Lakhasly

This review was conducted according to the guidelines outlined in Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The (PRISMA) Statement [30].Information Sources and Search Strategy The Medline bibliographic database of the National Library of Medicine, accessed through the National Institutes of Health's PubMed online resource, was searched for articles to include in this review.Eligibility Criteria Manuscripts considered eligible for this review included only: i. original published articles, and ii. observational or experimental studies.We found 27 papers that met these criteria.3.1.3.2.

This review was conducted according to the guidelines outlined in Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The (PRISMA) Statement [30].

3.1. Eligibility Criteria
Manuscripts considered eligible for this review included only: i. original published articles, and ii. observational or experimental studies. We found 27 papers that met these criteria.

3.2. Information Sources and Search Strategy
The Medline bibliographic database of the National Library of Medicine, accessed through the National Institutes of Health’s PubMed online resource, was searched for articles to include in this review. The primary search included the following key words: “sickle cell disease” AND “bone” AND “metabolism” AND “biochemical” AND “instrumental” AND “biological” AND “growth” AND “endocrine complications”. Additionally, articles referenced by those identified in this search were reviewed for relevance.

3.3. Study Selection
Articles were reviewed to determine if bone metabolism was assessed in the study population. Experimental studies were included only if the authors assessed markers of bone metabolism at baseline or before any treatment began.

3.4. Data Collection Process and Data Items
For each study that was considered eligible, the following data were collected: number and age of subjects, presence or lack of a comparison group, clinical parameters, biomarkers of bone turnover, and prevalence of metabolic or endocrine complications.